تحلیل اختیاری محصول
با اجازه شما، از تحلیلهای محدود و حریمخصوصیمحور استفاده میکنیم تا مسیرهای پژوهشی مؤثر را بشناسیم. از ردیاب تبلیغاتی یا بازپخش نشست استفاده نمیکنیم. این انتخاب را میتوانید در تنظیمات تغییر دهید. بخوانید سیاست حفظ حریم خصوصی.
Edwards Lifesciences Corporation's published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $49.3B | |
|---|---|---|
| Revenue (ttm) | 6.5B | |
| Net income (ttm) | 1B | |
| EPS (ttm) | $1.72 | |
| Shares out | 576.4M | |
| P/E (trailing) | 53.2x | |
| P/E (forward) | 25.6x | |
| Volume | 1,655,953 | |
| Beta | 0.86 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $5.23B | $4.46B | $5.01B | $5.44B | $6.07B | +3.8% |
| Gross profit | $3.98B | $3.74B | $4.03B | $4.32B | $4.73B | +4.4% |
| Operating income | $1.69B | $1.50B | $1.31B | $1.38B | $1.26B | -7.0% |
| Net income | $1.50B | $1.52B | $1.40B | $4.17B | $1.07B | -8.1% |
| EPS (diluted) | $2.38 | $2.44 | $2.30 | $6.97 | $1.83 | -6.4% |
| EBITDA | $1.89B | $1.96B | $1.53B | $1.72B | $1.43B | -6.7% |
| R&D | $903.1M | $843.6M | $962.9M | $1.05B | $1.08B | +4.6% |
| SG&A | $1.49B | $1.36B | $1.58B | $1.79B | $2.09B | +8.7% |
Recent company headlines from major financial publishers.
Edwards maintains durable leadership in transcatheter heart valve replacement, supported by specialized clinician workflows and expanding center capacity under finalized NCD guidelines,. Revenue grows in line with consensus projections across FY2026 and FY2027 before fading toward terminal rates by FY2030. Operating margins expand from FY2026 through FY2030, supported by premium gross margins. Reinvestment moderates relative to NOPAT as capital expenditures scale down relative to revenue from FY2025 levels.
Accelerated implementation of finalized National Coverage Determination (NCD) policies opens substantial hospital cath lab capacity and center access, reigniting US TAVR procedural growth while early-stage asymptomatic indication expansions broaden the eligible patient population. Emerging transcatheter mitral and tricuspid therapies scale rapidly, lifting consolidated gross margin and operating margin. Normalizing capex intensity relative to revenue expands annual cash flows, driving accelerated share repurchases and compound earnings expansion.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 7.9% | $64.3 | $66.0 | $68.1 | $70.7 | $73.8 |
| 8.4% | $61.6 | $63.1 | $64.8 | $66.9 | $69.4 |
| 8.9% | $59.3 | $60.6 | $62.3 | $63.7 | $65.7 |
| 9.4% | $57.3 | $58.3 | $59.5 | $60.9 | $62.6 |
| 9.9% | $55.4 | $56.3 | $57.4 | $58.5 | $59.9 |
Upcoming earnings date and setup when available.
رتبهای که نسخهٔ پژوهشی منتشرشدهٔ هر ماه داشت. رتبه قیمت در تاریخ تحلیل را با ارزش منصفانه مقایسه میکند و سابقهای از درستی یا نادرستی ارزیابی نیست.
| سال | دی | بهمن | اسفند | فروردین | اردیبهشت | خرداد | تیر | مرداد | شهریور | مهر | آبان | آذر |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
